Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial Multiple Sclerosis drug

10-Aug-2015 - United Kingdom

Apitope announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467, an investigational immune-tolerising agent. It is currently being tested in an open-label, one-arm proof-of-principle trial to evaluate its safety and effect on immune tolerance in subjects with relapsing multiple sclerosis (MS).

ATX-MS-1467 is a potential novel treatment developed with the aim of working with the immune system to treat the underlying cause of the disease by restoring immunological balance, instead of only treating the symptoms or suppressing the entire immune system.

Examination of the Phase I MRI results demonstrated a significant decrease of 78% in the number of contrast-enhancing brain lesions in patients with relapsing MSwith ATX-MS-1467.

Merck Serono will complete all development activities from the beginning of Phase II clinical trials.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances